<DOC>
	<DOCNO>NCT00391092</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety Avastin plus Herceptin/docetaxel , versus Herceptin/docetaxel alone , patient HER2 positive locally recurrent metastatic breast cancer receive prior chemotherapy metastatic disease . Patients randomize 1:1 receive either Avastin ( 15mg/kg iv q3weeks ) + Herceptin ( 8mg/kg iv load dose 6mg/kg iv q3weeks maintenance ) + docetaxel ( 100mg/m2 iv q3weeks ) Herceptin + docetaxel alone . The anticipated time study treatment disease progression , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Herceptin ( Trastuzumab ) /Docetaxel Patients With HER2 Positive Metastatic Breast Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; HER2 positive breast cancer locally recurrent metastatic lesion ; eligible chemotherapy ; baseline LVEF &gt; =50 % . previous chemotherapy metastatic locally recurrent breast cancer ; previous radiotherapy metastatic breast cancer ( except metastatic bone pain relief ) ; primary tumor within last 5 year , exception basal squamous skin cancer , situ cancer cervix ; clinically significant cardiovascular disease ; chronic daily treatment aspirin ( &gt; 325mg/day ) clopidogrel ( &gt; 75mg/day ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>